Below is a summary of a recent article on research on metabolic effects of Sapropterin treatment in autism spectrum disorder.
Sapropterin, a synthetic form of tetrahydroiopterin (BH4) has been reported to improve symptoms of children with autism spectrum disorder (ASD). Dr. Richard Frye, Director of the Autism Research Program at Arkansas Children's Hospital Research Institute, led a group of researchers in further investigating which metabolic pathways were associated with improvements seen due to BH4 treatment. Their findings support previous research results that BH4 treatment can be effective for treating symptoms associated with ASD, and add that response to BH4 treatment may primarily involve nitric oxide (NO) and BH4 metabolism and suggest biomarkers of NO metabolism may be helpful in predicting response to BH4 supplementation.
You can find the article online by searching for Frye, Sapropterin and Autism